Cancer Surgery
Open Access

Melanoma, a highly aggressive form of skin cancer, is notorious for its propensity to metastasize, leading to poor patient prognosis and high mortality rates. Surgical resection of melanoma tumors remains the cornerstone of treatment, especially in early-stage disease. However, despite successful tumor removal, many patients experience postoperative metastasis, which severely impacts long-term survival rates. The ability to predict which patients are at a higher risk of metastatic spread following surgery would enable clinicians to tailor postoperative therapies, improving outcomes and minimizing unnecessary treatments for low-risk patients. One promising avenue of investigation involves the role of tumor-infiltrating lymphocytes (TILs) as predictive biomarkers for postoperative metastasis. TILs, which are immune cells present within the tumor microenvironment, have garnered increasing attention in recent years due to their potential to influence tumor behavior and patient prognosis. This article explores the role of TILs in melanoma and their potential utility as biomarkers for predicting postoperative metastasis [1].

Tumor-Infiltrating Lymphocytes and Their Role in Melanoma Immunology

TILs consist of various subsets of immune cells, including T cells, B cells, macrophages, and dendritic cells, that infiltrate the tumor microenvironment in response to the presence of tumor antigens. In melanoma, T cells, particularly CD8+ cytotoxic T lymphocytes (CTLs), play a critical role in recognizing and attacking tumor cells. The presence of a high number of TILs, especially those with a cytotoxic profile, has generally been associated with improved patient outcomes, as these cells are thought to facilitate immune surveillance and tumor control. However, the relationship between TILs and patient prognosis is complex and context-dependent. While an abundance of TILs often indicates a robust immune response against the tumor, factors such as the functional state of the TILs, the immunosuppressive tumor microenvironment, and the ability of the tumor to evade immune detection can influence the effectiveness of TIL-mediated immune responses [2 ]. In melanoma, the composition and density of TILs within the tumor have been shown to correlate with prognosis. High levels of TIL infiltration, particularly of CD8+ T cells, are often associated with better survival rates and lower risk of metastasis. Conversely, tumors with low or dysfunctional TIL populations may have a greater ability to evade the immune system, leading to a higher likelihood of metastatic spread after surgery. This suggests that the assessment of TILs within the primary tumor could offer valuable insights into the likelihood of postoperative metastasis and guide treatment decisions [3].

Mechanisms by Which TILs Influence Metastasis in Melanoma

The role of TILs in melanoma metastasis is multifaceted. On one hand, TILs, particularly CD8+ T cells, exert direct anti-tumor effects by recognizing and killing melanoma cells that express tumor-specific antigens. This immune surveillance helps to prevent the spread of cancerous cells to distant organs. Additionally, TILs can promote the recruitment and activation of other immune cells, such as natural killer (NK) cells and macrophages, which further enhance the immune response against the tumor. These immune cells work in concert to limit the growth and spread of melanoma cells. On the other hand, the tumor microenvironment can influence the function and effectiveness of TILs. Melanomas are known to develop various immune evasion strategies, including the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which can suppress the activity of effector T cells and prevent a robust immune response. In addition, the production of immunosuppressive cytokines, such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), by melanoma cells can inhibit the function of TILs, allowing the tumor to escape immune surveillance and promoting metastasis. Therefore, the balance between immune activation and immune suppression within the tumor microenvironment, mediated in part by TILs, is critical in determining whether the melanoma will remain localized or metastasize [4].

TILs as Predictive Biomarkers for Postoperative Metastasis in Melanoma

Given the central role of TILs in melanoma progression and metastasis, there is growing interest in evaluating TILs as predictive biomarkers for postoperative metastasis. A high density of tumor-infiltrating CD8+ T cells is often considered a favorable prognostic factor, as it suggests an active immune response capable of controlling tumor growth and limiting metastatic spread. Conversely, a paucity of TILs or the presence of immunosuppressive TIL populations may indicate an increased risk of postoperative metastasis [5]. Several studies have investigated the prognostic value of TILs in melanoma, with mixed results. Some studies have found that higher TIL density is associated with improved survival and reduced risk of metastasis, while others have shown that the mere presence of TILs is insufficient to predict metastasis without considering the functional characteristics of these immune cells. In particular, the ratio of cytotoxic CD8+ T cells to regulatory T cells (Tregs) has been suggested as a more accurate predictor of metastatic risk. A higher proportion of CD8+ T cells relative to Tregs may indicate a more effective anti-tumor immune response, while a predominance of Tregs may signal immune suppression and an increased likelihood of metastasis. Furthermore, the molecular characteristics of TILs, including their expression of specific immune checkpoints such as PD-1, CTLA-4, and TIM-3, may provide additional insights into their functional state and ability to mount an effective immune response [6]. Tumors with TILs that express high levels of immune checkpoint molecules may be more likely to evade immune detection, leading to a higher risk of metastatic spread after surgery. These findings highlight the complexity of using TILs as predictive biomarkers for postoperative metastasis and suggest that a multifaceted approach, considering both the quantity and quality of TILs, may be required to accurately predict outcomes [7].

Clinical Implications and Future Directions

The potential to use TILs as predictive biomarkers for postoperative metastasis in melanoma surgery could have significant clinical implications. If validated, the assessment of TILs could be incorporated into routine clinical practice to help stratify patients based on their risk of metastatic recurrence [8]. This could enable clinicians to identify high-risk patients who may benefit from adjuvant therapies, such as immune checkpoint inhibitors or targeted therapies, aimed at enhancing the immune response and preventing metastasis. Conversely, patients with low-risk TIL profiles may avoid unnecessary treatments, reducing the burden of side effects and improving quality of life. However, several challenges remain in translating TILs as biomarkers into clinical practice. The heterogeneity of TIL populations, differences in immune microenvironments, and the complexity of immune evasion mechanisms in melanoma make it difficult to develop standardized assays for TIL evaluation [9 ]. Additionally, the timing of TIL assessment, whether it should be done preoperatively, intraoperatively, or postoperatively, needs further clarification. Future research should focus on refining the methodology for evaluating TILs, understanding their functional status, and identifying additional markers that can complement TIL density in predicting metastasis [10].

Conclusion

Tumor-infiltrating lymphocytes have emerged as promising candidates for predicting postoperative metastasis in melanoma surgery. While the presence of TILs, particularly cytotoxic CD8+ T cells, has generally been associated with better outcomes, the complex nature of the tumor microenvironment and immune evasion mechanisms in melanoma requires a more nuanced understanding of TIL function. By integrating TIL density with other immunological markers and considering the overall immune landscape of the tumor, clinicians may be able to more accurately predict the risk of metastasis and tailor postoperative therapies accordingly. Further research is needed to validate the use of TILs as predictive biomarkers and to establish standardized protocols for their clinical application in melanoma management.

1. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al. (1980)Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.Am J Med 69: 491-497.

Indexed at, Google Scholar, Crossref

2. Correia MI, Waitzberg DL (2003)The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis.Clin Nutr22: 235-239.

Indexed at, Google Scholar, Crossref

3. Søndenaa K, Quirke P, Hohenberger W, Sugihara K, Kobayashi H, et al. ( 2014)The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery. Int J Colorectal Dis 29: 419-428.

Indexed at, Google Scholar, Crossref

4. Dogan NU, Dogan S, Favero G, Köhler C, Dursun P, et al. (2019)The Basics of Sentinel Lymph Node Biopsy: Anatomical and Pathophysiological Considerations and Clinical Aspects. J Oncol 3415630.

Indexed at, Google Scholar, Crossref

5. Deijen CL, Vasmel JE, de Lange-de Klerk ESM, Cuesta MA, Coene PLO, et al. ( 2017)Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer. Surg Endosc. 31: 2607-2615.

Indexed at, Google Scholar, Crossref

6. Nunobe S, Hiki N, Fukunaga T, Tokunaga M, Ohyama S, et al. (2008)Previous laparotomy is not a contraindication to laparoscopy-assisted gastrectomy for early gastric cancer.World J Surg32: 1466-1472.

Indexed at, Google Scholar, Crossref

7. Osborne MP (2007)William Stewart Halsted: His life and contributions to surgery. Lancet Oncol 8: 256-265.

Indexed at, Google Scholar, Crossref

8. Fisher B (1977)United States trials of conservative surgery. World J Surg 1: 327-330.

Indexed at, Google Scholar, Crossref

9. Heald RJ, Husband EM, Ryall RD (1982)The mesorectum in rectal cancer surgery-the clue to pelvic recurrence?.Br J Surg 69: 613-616.

Indexed at, Google Scholar, Crossref

10. Vennix S, Pelzers L, Bouvy N, Beets GL, Pierie JP, et al. (2014)Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst 005200.

Indexed at, Google Scholar, Crossref